Hederagenin

Cat. No.: HY-N0256
CAS No.: 465-99-6
Molecular Formula: C₃₀H₄₈O₄
Molecular Weight: 472.7
Target: Others
Pathway: Others
Storage:
- Powder: -20°C for 3 years, 4°C for 2 years, In solvent: -80°C for 6 months, -20°C for 1 month

BIOLOGICAL ACTIVITY

Description
Hederagenin is a triterpenoid saponin. It can inhibit LPS-stimulated expression of iNOS, COX-2, and NF-κB. Hederagenin can exhibit multiple pharmacological activities in the treatment of hyperlipidemia, antilipid peroxidation, antiplatelet aggregation, liver protection, antidepressive, anti-inflammation. [1] In vitro: 1) Hederagenin can correct the imbalance of endothelial function by inhibiting the release of large amounts of iNOS and increasing eNOS contents and inhibiting the IKKβ/NF-κB signaling pathway to reduce the release of IL-6, IFN-γ, TNF-α, and other inflammatory factors. [1][2] The EC50 of hederagenin is 39 ± 6 μM in A549 cancer cell line, but it’s inactive for DLD-1 cells. [2][3] Hederagenin inhibited LPS-induced production of NO, PGE2 and cytokines in cells. [3][4] Hederagenin had an anti-edema effect on the CA-induced mouse hind paw edema assay. [3][5] Hederagenin inhibited the CA-induced increase in skin thicknesses. [3][6] In vivo: The rats in the hederagenin group were administered hederagenin at 20 mg/kg/d via gavage. (More details please refer to the protocol below). In AS rat models induced by a high-lipid diet plus VD3, hederagenin can effectively reduce serum lipid, ALT, and AST levels, in addition to improving liver function, relieving high blood coagulation, and slowing blood flow and stasis by improving blood rheology. [1]

REFERENCES


Caution: Product has not been fully validated for medical applications. For research use only.
Tel: 609-228-6898  Fax: 609-228-5909  E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA